Applied Therapeutics Announces New Chief Medical Officer

Applied Therapeutics ( (APLT) ) just unveiled an announcement.

On June 17, 2025, Applied Therapeutics announced the departure of Riccardo Perfetti as Chief Medical Officer, effective June 15, 2025, with Evan P. Bailey appointed as his successor. Dr. Bailey, who joined the company in 2021, brings extensive experience from his previous roles at Vertex Pharmaceuticals and as a pediatric pulmonologist. The company also shared full 12-month clinical results and new topline data from its Phase 2/3 INSPIRE trial for govorestat, showing statistically significant improvements in secondary endpoints and safety over 24 months, which could enhance its market positioning in treating SORD Deficiency.

The most recent analyst rating on (APLT) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Applied Therapeutics stock, see the APLT Stock Forecast page.

Spark’s Take on APLT Stock

According to Spark, TipRanks’ AI Analyst, APLT is a Underperform.

Applied Therapeutics is in the early stages of revenue generation, but significant challenges in achieving profitability and sustaining operations through negative cash flow pose risks. The technical analysis shows downward momentum, and valuation metrics reflect its current unprofitability. Focus remains on operational improvements and expense management to navigate financial instability.

To see Spark’s full report on APLT stock, click here.

More about Applied Therapeutics

Applied Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing transformative drugs for rare diseases. The company is primarily engaged in the clinical development of govorestat, a treatment for Sorbitol Dehydrogenase (SORD) Deficiency, a subtype of Charcot-Marie-Tooth disease.

Average Trading Volume: 2,168,143

Technical Sentiment Signal: Sell

Current Market Cap: $52.41M

See more insights into APLT stock on TipRanks’ Stock Analysis page.